SS-31 (10mg & 50mg)

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide investigated for its ability to stabilize cardiolipin on the inner mitochondrial membrane, supporting mitochondrial bioenergetics and reducing oxidative stress. It is widely studied in research contexts relating to cellular aging, metabolic health, and tissue resilience. Each vial is lyophilized from a sterile-filtered solution and validated by HPLC to a minimum of 99% purity. For research use only.

SS-31 (10mg & 50mg) appears in aging-research panels designed to compare peptide candidates across standardized metabolic readouts.

Work with SS-31 (10mg & 50mg) emphasizes batch-to-batch purity confirmation, with COA documentation supporting study reproducibility.

Current investigation of SS-31 (10mg & 50mg) focuses on its stability under storage conditions and its signaling activity in vitro.

This product is available in 10mg and 50mg. Each vial contains lyophilized peptide at the labeled quantity; wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only —not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with SS-31 (10mg & 50mg). Summaries are provided for orientation only and reflect the cited sources.

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics^[1] —This paper describes elamipretide (SS-31) as a first-in-class compound that protects cardiolipin and restores mitochondrial bioenergetics. The author discusses the peptide's selective interaction with the inner mitochondrial membrane. The work positions SS-31 as a therapeutic agent for conditions involving mitochondrial dysfunction. (British journal of pharmacology 2014)

Elamipretide: a mitochondria-targeting drug for Barth syndrome^[2] —This review discusses elamipretide as a mitochondria-targeting drug under investigation for Barth syndrome. The authors summarize the peptide's cardiolipin-binding mechanism and its clinical development. The review highlights the therapeutic potential of elamipretide in mitochondrial disease. (Trends in pharmacological sciences 2026)

Elamipretide in pediatric Barth syndrome: from heart failure to school return^[3] —This study reports on the use of elamipretide in pediatric patients with Barth syndrome, following outcomes from heart failure to functional recovery. The authors describe clinical observations associated with treatment. The findings suggest the peptide may offer benefit in this rare mitochondrial cardiomyopathy. (Orphanet journal of rare diseases 2026)

SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome^[4] —This study examined the effects of SS-31 on cardiac mitochondria in a murine model of Barth syndrome. The authors report that treatment ameliorates mitochondrial morphology and defective mitophagy. The results support the peptide's cardiolipin-targeting mechanism in a disease-relevant model. (Scientific reports 2024)

References

1. Szeto HH. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British journal of pharmacology. 2014. pubmed.ncbi.nlm.nih.gov/24117165/
2. Villatore A, Ehle EA, Chelko SP. "Elamipretide: a mitochondria-targeting drug for Barth syndrome." Trends in pharmacological sciences. 2026. pubmed.ncbi.nlm.nih.gov/42448476/
3. Amedro P, Andrianoely M, Gohier P, Leroux J, Aladjidi N, Lagorce S, Daccord M, Audie M, Botte A, Nubret K, Richard P, Roche S, Lamireau D, Tetard C, Trimouille A, Desir A, Mesli S, Donadieu J, Gotchac J. "Elamipretide in pediatric Barth syndrome: from heart failure to school return." Orphanet journal of rare diseases. 2026. pubmed.ncbi.nlm.nih.gov/42415111/
4. Russo S, De Rasmo D, Rossi R, Signorile A, Lobasso S. "SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome." Scientific reports. 2024. pubmed.ncbi.nlm.nih.gov/38871974/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.